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Hepatitis C Virus (HCV) infection is a serious cause of chronic liver disease worldwide with 
more than 170 million infected individuals at a risk of developing significant morbidity and 
mortality. Till date there is no effective drug for the treatment or vaccine to prevent this 
infection. The present study aims in discovering novel inhibitors which target an allosteric 
binding site of RNA dependent RNA polymerase enzyme of HCV. A structure based virtual 
screening of Zinc database by computational docking and the post docking analysis of energy 
calculations and interactions followed by ADMET studies were conducted. Our study revealed 
10 compounds which has more potential than the existing inhibitor to be considered as lead 
compounds. 
 
Introduction 
Hepatitis C Virus (HCV) is the main known causative agent for non  A non B chronic viral 
hepatitis in humans, it is estimated that 170 million people has been infected worldwide. [1] The 
main route of the infection is through contaminated blood and all other mean of exposures that 
ranges from needle prick among drug abusers and unprotected sex.[2] The acute infection will 
become chronic, leading to liver cirrhosis, hepatocelluar carcinoma and liver failure. Till date 
there is no effective vaccine available to prevent the disease, or a proper treatment regime to cure 
the infected [3,4]. Hence a large amount of resources are being utilised to discover a novel drug 
molecule which can clear the virus and cure the infection with minimum side effect and 
maximum efficacy. At present pegylated interferon, which generally targets the immune system 
and the purine analogue ribavarin are used against HCV. The combination of ribavarin and 
pegylated interferon is not specific to HCV infection and also associated with significant side 
effect.[5] The HCV NS5B protein is a 65 kDa protein formed of the C-terminal 591 amino acids 
of the polyprotein. An RNA dependent RNA polymerase (RdRp) activity was predicted for the 
NS5B gene product due to the presence of the Gly-Asp-Asp motif (GDD) that is common to the 
reverse transcriptases and other viral polymerases [5]. This was later confirmed in vitro by 
experiments using recombinantly expressed NS5B protein [6].  The active RdRp enzyme 
requires divalent metal ions and uses the RNA template strand to direct the synthesis of a 
complementary strand. Divalent manganese ions (Mn2+) are preferred over magnesium ions 
(Mg2+) for optimal enzyme activity, whereas zinc ions (Zn2+) inhibit the RdRp activity [7].  
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HCV RdRp consists of 21 α-helices and 18 β-strands. The catalytic domain consists of 
531 residues folded into characteristic fingers, palm and thumb subdomains. The NS5B adopts a 
unique globular shape due to extensive interactions between the fingers and thumb subdomains 
that serve to encircle the active site of the enzyme [8].  
HCV NS5B is an obvious and important target for therapeutic intervention aimed at 
inhibiting HCV replication. The rational approaches of drug designing which target NS5B have 
identified several classes of inhibitor molecules. But, a nucleoside analogue NM283 is the only 
inhibitor that has demonstratable levels of antiviral activity in human subjects [9]. Chemically, 
NM283 is a 2’-C-methyl cytidine. Resistance to NM283 has been reported in sub-genomic 
replicons. Substitution of the amino acid serine at position 282 with threonine was seen to confer 
resistance to 2’-C-methyl ribonucleosides by efficient discrimination between the analogues and 
the natural substrates [10]. Two non-nucleoside inhibitors of HCV NS5B, JTK 109 and JTK-003 
are also under clinical trials. These are benzimidazole compounds and act as allosteric inhibitors 
of NS5B. Replacement of proline 495 with alanine or leucine is found to confer resistance 
against these compounds in sub genomic replicons [11]. Several other compounds of the 
benzothiadiazine class are also being investigated. However, a cause for concern is the 
observation that the subgenomic mutants develop resistance against benzothiadiazines [12]. The 
allosteric binding sites may be far away from the usual binding site of the protein, but binding of 
a small molecules to these sites may alter the function of the protein [13].  Crystallographic study 
by Di Macro et al. 2005 [14] revealed that a allosteric non-nucleoside inhibitor (NNI) binding 
site can be targeted for small molecule search. This novel allosteric binding site can lead a new 
path in discovering effective inhibitors against the polymerase enzyme. 
Here we identified 10 small molecules which show more efficacy than existing inhibitor 
bound to the protein through molecular docking and ADME analysis. 
 
Methodology 
 
The 3D structure of HCV NS5B bounded with an allosteric inhibitor were retrieved from Protein 
databank, accession code 2BRK was found to bound to an allosteric inhibitor named compound 
1. The ligand bounded with the protein was re-docked inorder to obtain binding affinity 
information. The active residues were identified as the neighbouring amino acids with in 10 Å 
distance from the bounded ligand. 
 
Virtual screening using Zinc database 
The ZINC database is a curated collection of commercially available chemical compounds 
prepared especially for virtual screening [15]. ZINC is used by investigators (generally people 
with training as biologists or chemists) in pharmaceutical companies, biotech companies, and 
research universities. There are many subsets available in the Zinc database. We had selected 
leads now subset containing 1,283,469 molecules which are kept ready to perform virtual 
screening. 
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Molecular Docking 
Molecular docking was carried out using GOLD 4.1(Genetic Optimization of Ligand Docking) 
[16]. The parameters used for genetic algorithm were population size - 100, selection pressure - 
1.1, number of operations - 100,000, number of islands - 5, niche size - 2, migrate - 10, mutate - 
95  and cross-over - 95. The default speed selection was used to avoid a potential reduction in 
docking accuracy. Fifty genetic algorithm runs with default parameter settings were performed 
without early termination for both the Gold score and Chem score. The whole protein complex 
were used for Molecular Docking run in order to obtain maximum accurate binding possibility. 
The best binding pose were determined after careful visualisation and considering the scoring 
function. 
 
ADME Prediction (Absobtion, Distribution, Metabolism, Excretion) 
Predicting physiochemical properties of a chemical compound will always cut short the 
expensive experimental testing and hard labour. Molecular Docking studies revealed that 10 
compounds from the Zinc small molecule databank  has potential binding affinity towards HCV 
NS5B RdRp. Hence, the ADME predictions of these compounds was carried out using freely and 
commercially available web based ADME Boxes developed by Pharmaco Algorithms 
(http://pharmaalgorithms.com/webboxes/). It is a software module that calculates physiochemical 
properties, oral availability (human), human intestinal absorption, plasma bound distribution 
based on the chemical structure. 
 
Results and Discussion 
The HCV NS5B is the RNA dependent RNA polymerase responsible for replication of the viral 
genome and is a key target for the therapeutic intervention against HCV. The ADME/T 
characteristics of the compound reveal that it has high mutagenic potential which increases its 
toxicity. The LD50 studies also showed that it had to be administered at high dosages which 
would again increase its toxicity. It has low solubility characteristics in various pH and it is 
highly insoluble in water. Upon docking, Compound 1 showed a GOLD score and Chem score 
of 46.50 and 13.56. These drawbacks indicate the need for an effective drug that can replace this 
molecule. All the lead candidates that were shortlisted from small molecule databases had better 
docking scores than the known ligand.(see table 1.) 
The lead candidates Lipoxin A4, Fluprostenol displayed excellent oral bioavailability and 
distribution characteristics. They had weak acidic character and obeyed Lipinski’s Rule. They 
showed moderate to low solubility in various pH and water and do not act as P-gp substrates. 
They exhibited low probability of mutagenic potential and the LD50 studies suggested 
intravenous route of administration for mice and intraperitoneal route of administration for rats at 
low dosage forms. 
The lead candidate Leukotriene E4 showed limited ability to cross the intestinal barrier by 
passive diffusion, hence affecting its oral bioavailability. It had good distribution characteristics 
and behaved as a weak base. It obeyed Lipinski’s rule, had moderate to low solubilities in 
various buffers and water and does not act as a P-gp substrate. It showed moderate probability of 
acting as a mutagen thereby increasing its toxicity.  
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The lead candidates Lactacystin, Diethylnorspermine showed limited ability to cross the 
intestinal barrier by passive diffusion, hence affecting their oral bioavailability. They had low 
protein binding efficiency thereby affecting its distribution. They showed low probability of 
acting as P-gp substrates. They showed basic character, obeyed Lipinski’s rule and had good 
solubilities in various buffers and water. They also displayed low probability of acting as a 
mutagen and was required to be delivered in low dosage inspite of the route of administration. 
The lead candidates Thromboxane B2, Leukotriene B3, 17-phenyl-trinor-pge2 and 
Misoprostol free acid displayed good oral bioavailability and distribution characteristics. They 
had strong acidic character and obeyed Lipinski’s Rule. They showed moderate solubility in 
various pH while it was insoluble in water. They showed low probability of acting as a P-gp 
substrate. They exhibited low probability of mutagenic potential and the LD50 studies suggested 
intraperitoneal route of administration for mice and rats at low dosage forms for Thromboxane 
B2 and intravenous route for mice in the case of Leukotriene B3, 17-phenyl-trinor-pge2. 
The lead candidate Lavendustin A shows high probability of undergoing first pass metabolism 
thereby affecting its oral bioavailability. It displayed good distribution characteristics and did not 
act as a P-gp substrate. It had both acidic and basic groups with a majority of the former. It 
obeyed Lipinski’s rule and had low solubility in various buffers and water. It had low mutagenic 
potential and the LD50 studies showed that the preferred route of administration was intravenous 
in mice and intraperitoneal in rats. After experimental validations and pre clinical studies one 
among these 10 molecule can replace the existing inhibitors and can be a good drug candidate 
against HCV infection. 
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 SL 
NO. 
 
LIGAND 
 
HYDROGEN 
BONDING 
RESIDUE 
 
NO. OF 
H 
BONDS 
(distance 
<3 Ǻ) 
 
CLOSE 
CONTACTS 
(<3 Ǻ) 
DISTAN
CE 
FROM 
CLOSE 
CONTA
CT (Ǻ) 
 
GOLD 
SCORE 
 
CHEM 
SCORE 
1. COMPOUND 1 Arg 503 
2 
(1.666) 
- - 60.50 13.56 
Leu 492 
2 
(2.482) 
Gly 493 
1 
(2.262) 
Val 494 
1 
(1.927) 
Arg 503 
1 
(2.284) 
 
2. 
 
LIPOXIN A4 
 
 
 
Trp 500 
2 
(2.202) 
 
Val 494 
 
2.647 
 
81.50 
 
21.70 
Arg 503 
4 
(1.661) 
 
Pro 495 
 
2.735  
3. 
 
LEUKOTRIENE E4
Trp 500 
1 
(2.045) 
 
Trp 500 
 
2.371 
 
77.06 
 
18.36 
 
4. 
 
LEUKOTRIENE B3
Trp 500 
1 
(2.027) 
 
Arg 503 
 
2.735 
 
74.08 
 
22.98 
  
Arg 503 2
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(2.228) 
5. LACTACYSTIN 
Trp 500 
4 
(1.875) 
Pro 495 2.825 70.76 21.82 
Arg 503 
3 
(1.694)  
6. 
 
THROMBOXANE 
B2 Trp 500 
2 
(1.570) 
 
Arg 503 
 
2.535 
 
71.09 
 
15.71 
Arg 503 
3 
(1.727) 
Pro495 2.587 
 
7. 
17-PHENYL-
TRINOR-PGE2 
Trp 500 
4 
(1.970) 
Trp 500 2.489 
 
71.28 
 
21.20 
Arg 503 
3 
(1.694)  
8. 
 
DIETHYLNORSPE
RMINE 
 
 
Trp 500 
1 
(2.045) 
 
Trp 500 
 
2.857 
 
72.91 
 
18.91 
Trp 500 
2 
(2.728) 
Arg 503 2.565 
 
9. 
 
LAVENDUSTIN A 
Arg 503 
3 
(1.695) 
Trp 500 2.463 
 
73.47 
 
20.52 
 
Arg 503 
 
5 
(2.246) 
 
10. 
 
FLUPROSTENOL 
Trp 500 
2 
(1.640) 
 
- 
 
- 
 
73.60 
 
23.43 
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Table 1. Docking and post docking analysis of the lead compounds compare to compound 1. 
 
11. 
 
MISOPROSTOL 
FREE ACID 
 
Trp 500 
3 
(1.876) 
 
Pro 495 
 
2.569 
 
73.76 
 
17.36 
 
Molecules 2B
RK 
1 2 3 4 5 6 7 8 9 10 
Bioavailability 99.
88 
83.
62 
90.
22 
96.
93 
20.
62 
86.
84 
94.
15 
14.
86 
96.
48 
97.
15 
95.
86 
Volume of distribution -
0.4
0 
-
0.3
4 
0.3
5 
0.3
8 
0.2
5 
0.3
6 
-
0.3
5 
-
3.6
4 
-
0.2
3 
0.0
4 
0.5
4 
            
Mol.wt 446
.54 
352
.46 
439
.61 
338
.48 
376
.43 
370
.48 
385
.48 
244
.42 
381
.83 
458
.47 
368
.51 
H bond 
Acceptor 
6 5 6 4 9 6 5 4 7 6 5 
H bond 
donor 
1 4 5 3 5 4 3 4 5 4 3 Physiochemical properties 
Log P 5.5
7 
2.3
7 
2.4
8 
4.0
4 
-
1.1
3 
2.5
6 
2.9
9 
0.7
3 
2.8
3 
3.4
9 
3.3
9 
Solubility 1.0
0 
-
0.5
7 
-
3.2
7 
-
1.2
8 
0.8
1 
-
1.3
2 
-
0.6
6 
1.0
4 
-
2.3
9 
-
1.1
8 
-
1.2
7 
Ames test 0.9
37 
0.0
34 
0.4
57 
0.0
91 
0.2
71 
0.0
69 
0.0
16 
0.2
18 
0.0
02 
0.0
0 
0.0
03 
Oral 330
0  
160
0 
470
0 
170
0 
510 180
0 
150
0 
350 150
0 
120
0 
120
0 
Intraperit
onal 
140
0 
120 100
0 
150 88 120 130 100 300 270 110
Intraveno
us 
310 62 140 73 230 130 93 31 140 120 120LD50 
Subcutane
ous 
190
0  
610 220
0 
770 330 430 390 190 780 470 260
Table 2. ADMET of the compounds. 
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